Emcure Ahmedabad Unit Under USFDA Scanner, Gets 7 Procedural Observations

Written By :  Parthika Patel
Published On 2026-05-18 18:13 GMT   |   Update On 2026-05-18 18:13 GMT
Advertisement

New Delhi: Emcure Pharmaceuticals has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at its formulations manufacturing facility located at GIDC, Taluka-Sanand, Ahmedabad, Gujarat.

According to the company’s regulatory filing, the inspection was carried out from May 6, 2026 to May 15, 2026 at the formulations facility situated in Sanand, Ahmedabad.

At the conclusion of the inspection, the USFDA issued a Form 483 containing seven observations. The company clarified that all the observations issued by the US health regulator are procedural in nature.

A Form 483 is issued by the USFDA when investigators identify conditions that may indicate possible deviations from regulatory or manufacturing compliance requirements during an inspection.

Emcure Pharmaceuticals stated that it is comprehensively addressing the observations raised by the USFDA and will submit its response to the regulator within the stipulated timeframe.

The company disclosed the development through a regulatory filing submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Emcure further requested the stock exchanges to take the information on record.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News